NCT03709355View on ClinicalTrials.gov

Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

September 6, 2019

Study Completion Date

September 6, 2019

Conditions
HIV-1-infection
Interventions
DRUG

Elpida®

Elpida® capsules, 20mg

DRUG

Rifampin

Rifampin capsules, 150mg

DRUG

Rifabutin

Rifabutin capsules, 150mg

DRUG

Clarithromycin

Clarithromycin Film-coated tablets, 250mg

DRUG

Omeprazole

Omeprazole Film-coated tablets 20mg

DRUG

Atorvastatin

Atorvastatin Film-coated tablets, 80mg

DRUG

Levonorgestrel+Ethinylestradiol

Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets

Trial Locations (1)

143964

Central Clinical City Hospital, Reutov

Sponsors

Lead Sponsor

Viriom
All Listed Sponsors
lead

Viriom

INDUSTRY

NCT03709355 - Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs | Biotech Hunter | Biotech Hunter